查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1923028

無導管胰島素幫浦市場按糖尿病類型、性別、感測器使用時長、價格範圍、技術世代、最終用戶和分銷管道分類－2026-2032年全球預測

Tubeless Insulin Pumps Market by Type Of Diabetes, Connectivity, Sensor Wear Duration, Price Range, Technology Generation, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，無管胰島素幫浦市場價值將達到 13.8 億美元，到 2026 年將成長至 15.2 億美元，到 2032 年將達到 32.5 億美元，複合年成長率為 12.96%。

關鍵市場統計數據
基準年 2025 13.8億美元
預計年份：2026年 15.2億美元
預測年份 2032 32.5億美元
複合年成長率 (%) 12.96%

無導管胰島素幫浦發展趨勢的關鍵方向、以患者為中心的設計重點以及臨床和商業性需求的協調一致

無導管胰島素幫浦是糖尿病治療領域的一個轉捩點，它將緊湊的外形與日益精密的控制邏輯和感測器整合相結合，從而減輕了胰島素注射帶來的認知負擔。過去十年，持續血糖監測、無線連接和微型化胰島素輸注機制的進步，共同造就了這些以隱蔽佩戴、易用性和臨床互通性為核心的設備。這些特性重塑了臨床醫生、看護者和糖尿病患者的期望，簡化的給藥流程和設備小型化等以患者為中心的功能，已成為採購和實施決策的核心考量。

互聯互通、演算法控制和醫療服務模式創新正在融合，重新定義醫療服務普及趨勢和競爭優勢。

在技​​術融合、醫療服務模式的演變以及患者對無縫體驗日益成長的期望的推動下，無導管胰島素幫浦市場格局正在經歷變革性變化。其中最顯著的趨勢之一是將持續血糖監測數據與先進的演算法控制相結合，使設備從獨立的胰島素輸注工具發展成為支援生態系統的治療平台。這種轉變加速了對互通性標準、安全資料交換以及針對不同患者表現型的檢驗演算法效能的需求。

評估2025年新關稅政策將如何重塑無導管胰島素幫浦生態系統的供應鏈韌性、採購和定價動態。

美國2025年實施的新關稅對無導管胰島素幫浦價值鏈產生了複雜的影響，籌資策略、生產成本和分銷決策。精密泵浦、電子控制模組和感測器等組件通常依賴國際供應鏈，關稅可能會增加這些關鍵子組件的到岸成本，並促使製造商重新評估其供應商組合和合約條款。為此，許多企業正在權衡各種方案，包括自行承擔額外成本、調整價格或加快高價值組件的在地化生產。

綜合分析市場細分，整合臨床應用案例、終端用戶需求、連接方式、感測器使用壽命、價格範圍、代際技術差異。

細緻的市場細分框架揭示了無導管胰島素幫浦應用的多樣化臨床應用案例、商業管道和技術組合。依糖尿病類型分類，市場分析涵蓋第1型糖尿病和第2型糖尿病，重點在於不同患者群體所需的臨床通訊協定和治療強度差異。與僅依賴胰島素的2型糖尿病患者相比，自體免疫胰島素成癮患者通常需要更緊密地結合持續血糖監測，並採用更積極的自動化治療方案。按最終用戶分類，市場分析涵蓋成人和兒童，反映出他們在設備人體工學、黏合劑耐受性、看護者參與度和依從性等方面的顯著差異，這些差異需要透過有針對性的培訓和支援服務來解決。

區域實施的細微差別以及監管和報銷的實際情況正在影響美洲、歐洲、中東和非洲以及亞太地區的准入策略。

區域特徵影響無導管胰島素幫浦的推廣路徑和商業化策略，每個地區的法規環境、報銷模式和醫療服務體系各不相同。在美洲，完善的臨床路徑、廣泛的支付方框架和成熟的分銷網路支持著新設備概念的快速整合，同時，人們也越來越期望獲得可靠的療效數據和成本效益證據，以確保產品能夠順利納入醫保目錄。因此，面向美洲市場的製造商通常會優先考慮擴充性的支援服務、與電子健康記錄的互通性以及與大型綜合醫療網路的合作。

競爭定位和合作模式揭示了哪些產品特性、證據途徑和分銷策略能夠推動差異化和臨床應用。

無導管胰島素幫浦領域的競爭格局由成熟的醫療設備製造商、新興的數位醫療公司和專業組件供應商共同構成。現有醫療設備公司擁有監管方面的專業知識、臨床試驗基礎設施和廣泛的分銷網路，能夠加速產品在醫院和專科診所的推廣應用。同時，數位化原生的新興參與企業則專注於使用者體驗、快速迭代和軟體主導的差異化，旨在吸引那些重視簡化註冊流程和行動優先介面的使用者群體。

結合人性化的設計、證據產生、通路整合和彈性供應鏈的可操作策略重點，以加速產品推廣並維持成長。

希望充分利用無導管胰島素幫浦創新成果的領導者應採取整合策略，涵蓋產品設計、臨床證據、商業模式和供應鏈韌性。必須投資於迭代式、以人為本的設計，包括提升應用舒適度、針對不同年齡層客製化的設備人體工學設計，以及簡化用戶人性化以減輕培訓負擔並提高依從性。在產品改進的同時，應優先進行縱向臨床研究和真實世界證據項目，以量化患者報告結局、治療依從性和醫療資源利用率的改善。這些數據對於與支付方的討論和機構採購決策至關重要。

嚴謹的多方法研究，結合臨床醫生和患者的見解、監管和技術分析，以及透明的三角驗證，確保得出可操作且可靠的研究結果。

本研究採用多方面方法，整合定性和定量證據，全面考察無導管胰島素幫浦的技術、臨床和商業性特性。主要研究內容包括對內分泌領域關鍵意見領袖、糖尿病專科護理師、採購人員和支付者進行結構化訪談，以及從患者和看護者小組收集真實世界的使用體驗和依從性促進因素。這些第一手觀點與監管文件、臨床試驗註冊資訊和同行評審文獻進行交叉驗證，以確保研究結果的有效性，並確保設備性能聲明基於臨床實踐。

總之，該研究全面證明了需要協調臨床、商業性和營運要求，才能真正發揮無管胰島素幫浦技術的潛力。

總之，無導管胰島素幫浦為傳統幫浦系統提供了一種隱密、易用的替代方案，同時整合了持續監測和互聯護理平台，有望改變糖尿病治療格局。產品設計、臨床證據和商業性執行之間的相互作用將決定這些設備融入日常糖尿病管理的速度和範圍。因此，相關人員必須在創新與可操作的證據生成、監管策略以及管道可行性之間取得平衡，以確保設備進步能夠轉化為患者療效和醫療保健系統效率的持續改善。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依糖尿病類型分類的無導管胰島素幫浦市場

  • 1型糖尿病
  • 2型糖尿病

9. 無導管胰島素幫浦市場按連接方式和性別分類

  • Bluetooth
  • 細胞

10. 無導管胰島素幫浦市場按感測器配戴持續時間分類

  • 14天
  • 7天

第11章 無導管胰島素幫浦市場（依價格範圍分類）

  • 經濟
  • 中檔
  • 優質的

12. 以技術世代分類的無導管胰島素幫浦市場

  • 第一代
  • 第二代

第13章 無導管胰島素幫浦市場（依最終用戶分類）

  • 成人
  • 兒童

14. 無導管胰島素幫浦市場（依通路分類）

  • 線上
  • 離線

15. 無導管胰島素幫浦市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 無導管胰島素幫浦市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

17. 各國無導管胰島素幫浦市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

18. 美國無導管胰島素幫浦市場

第19章 中國無管胰島素幫浦市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Advanced Microfluidics SA
  • APEX Medical Devices
  • Ascensia Diabetes Care
  • Beta Bionics, Inc.
  • Bigfoot Biomedical, Inc.
  • Cam Med LLC
  • CareMedi Co., Ltd.
  • Cellnovo Group plc
  • CeQur Corporation
  • Debiotech SA
  • Diabeloop SAS
  • EOFlow Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Insulet Corporation
  • Johnson & Johnson
  • Luna Health Inc.
  • Medipacs Inc.
  • Medtrum Technologies Inc.
  • MicroPort Scientific Corporation
  • Modular Medical, Inc.
  • PharmaSens AG
  • Tandem Diabetes Care, Inc.
  • Terumo Corporation
  • Valeritas Holdings, Inc.
  • ViCentra BV
  • Ypsomed AG
Product Code: MRR-867BED9A9ED4

The Tubeless Insulin Pumps Market was valued at USD 1.38 billion in 2025 and is projected to grow to USD 1.52 billion in 2026, with a CAGR of 12.96%, reaching USD 3.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.38 billion
Estimated Year [2026] USD 1.52 billion
Forecast Year [2032] USD 3.25 billion
CAGR (%) 12.96%

An essential orientation to tubeless insulin pump developments, patient-centered design priorities, and alignment of clinical and commercial imperatives

Tubeless insulin pumps represent an inflection point in diabetes care, marrying compact form factors with increasingly sophisticated control logic and sensor integration to reduce the cognitive burden of insulin delivery. Over the past decade, advances in continuous glucose monitoring, wireless connectivity, and miniaturized insulin delivery mechanisms have converged to create devices that prioritize discrete wearability, ease of use, and clinical interoperability. These attributes have reshaped expectations among clinicians, caregivers, and people living with diabetes, with patient-centric features such as simplified dosing workflows and reduced device footprint becoming central criteria in procurement and adoption decisions.

From a clinical perspective, tubeless systems are positioned to address common adherence barriers by eliminating tubing-related tangles and improving comfort during activities of daily living. Consequently, stakeholders in ambulatory care, specialty clinics, and pediatric endocrinology have increasingly considered these devices when optimizing treatment regimens. At the same time, regulatory agencies and payers are emphasizing real-world evidence and post-market surveillance, which elevates the importance of robust clinical-data generation and longitudinal outcome tracking. In this context, manufacturers and health systems must align product development and reimbursement strategies to demonstrate not only device safety but also measurable improvements in quality of life and health resource utilization.

Looking ahead, the introduction and refinement of tubeless insulin pumps is likely to influence how multidisciplinary diabetes teams conceptualize therapy pathways. Strategic decisions around device interoperability, patient education, and remote monitoring will become critical success factors. As adoption pathways mature, leaders across clinical, commercial, and regulatory domains will need to collaborate to translate technological promise into accessible, durable solutions for diverse patient populations.

How converging innovations in connectivity, algorithmic control, and care delivery models are redefining adoption dynamics and competitive differentiation

The landscape for tubeless insulin pumps is undergoing transformative shifts driven by technological integration, evolving care delivery models, and heightened expectations for seamless patient experiences. One of the most consequential trends is the integration of continuous glucose monitoring data and advanced algorithmic control, which moves devices away from isolated insulin delivery tools toward ecosystem-enabled treatment platforms. This shift accelerates the demand for interoperability standards, secure data exchange, and validated algorithm performance across diverse patient phenotypes.

Concurrently, remote care and decentralized clinical pathways are reshaping go-to-market strategies. Telehealth adoption has expanded follow-up and titration touchpoints, reducing the friction associated with device initiation and enabling more frequent, data-driven adjustments. This change elevates the importance of cellular and Bluetooth connectivity options that support reliable telemetric transmission and remote clinician access. Additionally, sensor wear duration advancements-such as longer-use sensors-are driving user convenience and lowering the frequency of device handling, which in turn affects supply logistics and patient training protocols.

On the commercial side, segmentation by price tier and generation of technology encourages product differentiation and channel diversification. Manufacturers are balancing premium feature sets with economy options to reach broader patient cohorts, while second-generation platforms emphasize enhanced automation and user-friendly interfaces. Meanwhile, regulatory scrutiny and payer focus on demonstrable clinical benefit require that innovation be accompanied by strong real-world evidence programs. Therefore, companies that pair technical refinement with scalable clinical validation and robust patient support will capture the benefits of these transformative shifts and set new expectations for standard of care.

Assessing how new tariff policies in 2025 reshape supply chain resilience, sourcing choices, and pricing dynamics across the tubeless insulin pump ecosystem

The introduction of new tariff measures in the United States in 2025 has created a complex set of implications for the tubeless insulin pump value chain, influencing sourcing strategies, manufacturing economics, and distribution decisions. Components such as precision pumps, electronic control modules, and sensors often rely on international supply lines; tariffs can raise the landed cost of these critical subassemblies and prompt manufacturers to reassess their supplier portfolios and contractual terms. In response, many organizations are weighing the trade-offs between absorbing incremental cost, adjusting price points, or accelerating localization efforts for higher-value components.

Beyond direct cost impacts, tariffs alter strategic calculus for inventory management and capital allocation. Firms may increase buffer stocks or invest in dual-sourcing arrangements to mitigate disruption risk, which affects working capital requirements and operational agility. Distribution partners and channel intermediaries also feel downstream effects, as changes in unit economics can influence reimbursement negotiations and hospital procurement choices. For health systems operating under constrained budgets, even modest price movements can affect formulary positioning and the relative attractiveness of alternative therapies.

Moreover, tariffs can catalyze longer-term industry responses. Some manufacturers may pursue nearshoring or onshore assembly to reduce exposure, while others may redesign components to minimize tariff exposure by altering material composition or country of origin classifications. Policy uncertainty itself becomes a strategic factor, prompting scenario planning and heightened engagement with trade and regulatory advisors. In this evolving context, companies that proactively adapt supply chain design and maintain transparent dialogue with clinical and payer stakeholders will be better positioned to sustain access and preserve continuity of care.

Comprehensive segmentation insights that integrate clinical use cases, end-user needs, connectivity options, sensor durations, price tiers, and generational technology distinctions

A nuanced segmentation framework illuminates the varied clinical use cases, commercial channels, and technology permutations that define tubeless insulin pump adoption. Based on Type Of Diabetes, market is studied across Type 1 Diabetes and Type 2 Diabetes, which underscores the differing clinical protocols and therapy intensities required for each population; patients with autoimmune insulin dependence often require tighter integration with continuous glucose monitoring and more aggressive automation than those with insulin-requiring Type 2 disease. Based on End User, market is studied across Adults and Pediatrics, reflecting substantial variation in device ergonomics, adhesive tolerance, caregiver involvement, and adherence dynamics that must be addressed through targeted training and support services.

Consideration of distribution pathways is also central to strategy, as based on Distribution Channel, market is studied across Hospitals, Online Stores, Pharmacies, and Specialty Clinics; these channels each offer distinct procurement cycles, clinical support capabilities, and reimbursement interfaces, meaning manufacturers must tailor their commercial model and educational investments to suit each channel's cadence. From a connectivity standpoint, based on Connectivity, market is studied across Bluetooth and Cellular, which affects remote monitoring capabilities, battery management, and clinic-to-patient data workflows-Bluetooth solutions may favor proximity-based consumer devices while cellular options provide broader reach for continuous telemetric engagement.

Sensor logistics are likewise pivotal, because based on Sensor Wear Duration, market is studied across Fourteen Day and Seven Day, and these wear-time options influence user convenience, replacement cadence, and ancillary supply planning. Pricing stratification plays a role in access and adoption patterns, with based on Price Range, market is studied across Economy, Mid Range, and Premium tiers enabling manufacturers to balance affordability against feature richness and differentiated service levels. Finally, the evolution of product maturity is captured in the categorization based on Technology Generation, market is studied across First Generation and Second Generation, where second-generation devices prioritize enhanced automation, reliability, and ease of use born from iterative design and clinical feedback. Together, these segmentation lenses guide development choices, commercial targeting, and clinical evidence priorities that align with distinct stakeholder needs.

Regional adoption nuances and regulatory-reimbursement realities that influence access strategies across Americas, Europe Middle East Africa, and Asia-Pacific contexts

Regional dynamics shape adoption pathways and commercialization strategies for tubeless insulin pumps, with each geography presenting distinct regulatory environments, reimbursement models, and care delivery infrastructures. In the Americas, established clinical pathways, widespread payer frameworks, and mature distribution networks support rapid integration of new device paradigms, but they also raise expectations for robust outcomes data and cost-effectiveness evidence to secure favorable formulary placement. Consequently, manufacturers targeting the Americas often prioritize scalability of support services, interoperability with electronic health records, and alignment with large integrated delivery networks.

Turning to Europe, Middle East & Africa, diverse regulatory regimes and heterogeneous payer architectures create a mosaic of access challenges and opportunities. In Europe, centralized regulatory harmonization paired with country-specific reimbursement processes means that demonstrating health-economic value is essential for national and regional adoption. Meanwhile, in parts of the Middle East & Africa, infrastructure limitations and variability in specialist availability can necessitate different channel strategies, including education programs for primary care providers and partnerships with regional distributors to extend reach.

Asia-Pacific presents a wide spectrum of market maturity, from advanced digital health ecosystems with strong mobile penetration to emerging markets where affordability and distribution logistics are dominant concerns. Health system priorities in several APAC countries include local manufacturing incentives and public procurement frameworks, which can accelerate adoption for suppliers that align with localization expectations. Across regions, differences in clinical practice patterns, cultural attitudes toward wearable devices, and reimbursement modalities require a calibrated approach to product positioning, evidence generation, and channel enablement.

Competitive positioning and partnership patterns that reveal which product capabilities, evidence corridors, and distribution strategies drive differentiation and clinical uptake

Competitive dynamics in the tubeless insulin pump arena are defined by a combination of established device manufacturers, emerging digital health challengers, and specialized component suppliers. Incumbent medical device organizations bring experience in regulatory navigation, clinical trial infrastructure, and broad distribution networks, which can accelerate hospital and specialty clinic uptake. Meanwhile, digitally native entrants often focus on user experience, rapid iteration, and software-driven differentiation, positioning themselves to capture segments that prioritize streamlined onboarding and mobile-first interfaces.

Strategic partnerships and ecosystem plays are increasingly common as firms seek to combine hardware excellence with algorithmic and sensor expertise. Collaborations between pump developers, continuous glucose monitor providers, and cloud analytics platforms enable more cohesive value propositions and support integrated care pathways. In addition, manufacturing and supply-chain partners that specialize in miniaturized components and adhesive technologies are critical to product performance and cost structure. Across competitive moves, differentiation often rests on a few decisive factors: the quality of long-term clinical evidence, the reliability of remote monitoring and connectivity, the breadth of distribution channels supported, and the strength of post-sale patient support.

Companies that successfully navigate these dimensions cultivate clear clinical narratives, prioritize interoperable data strategies, and invest in durable service architectures that reduce friction across the patient journey. Those that do not align product capabilities with practical clinician workflows and payer evidence requirements may face adoption headwinds despite technical sophistication.

Actionable strategic priorities that link human-centered design, evidence generation, channel alignment, and resilient supply chains to accelerate adoption and sustain growth

Leaders seeking to capitalize on tubeless insulin pump innovation should adopt an integrated strategy that spans product design, clinical evidence, commercial model, and supply-chain resilience. Invest in iterative human-centered design that addresses adhesive comfort, device ergonomics for different age groups, and simplified user interfaces to reduce training burden and improve adherence. Parallel to product refinement, prioritize longitudinal clinical studies and real-world evidence programs that quantify improvements in patient-reported outcomes, therapy adherence, and health-resource utilization; these data are essential for payer conversations and institutional procurement decisions.

Commercially, align channel strategies to meet end-user needs by tailoring offerings for hospitals, specialty clinics, pharmacies, and direct-to-consumer channels, and ensure that distribution partners can provide clinical training and timely supply support. Implement pricing architectures that reflect differentiated value propositions across economy, mid-range, and premium segments while also exploring risk-sharing models with payers where evidence supports improved clinical outcomes. From a technology perspective, develop robust connectivity options encompassing Bluetooth for local device ecosystems and cellular for continuous remote monitoring, ensuring that data security and interoperability standards are met.

Finally, strengthen supply-chain flexibility to mitigate tariff and component risks by diversifying suppliers, evaluating nearshoring for critical subassemblies, and designing components for regulatory and tariff resilience. Complement these operational measures with a proactive stakeholder engagement plan that includes clinicians, payers, patient advocacy groups, and regulators to accelerate acceptance and reduce deployment friction.

A rigorous multi-method research approach combining clinician and patient insights, regulatory and technical analysis, and transparent triangulation to ensure practical and reliable findings

This research synthesizes qualitative and quantitative evidence through a multi-method approach designed to capture the technical, clinical, and commercial dimensions of tubeless insulin pumps. Primary research components include structured interviews with key opinion leaders in endocrinology, diabetes nurse educators, procurement specialists, and payers, alongside patient and caregiver panels to surface real-world usability insights and adherence drivers. These first-hand perspectives are triangulated with regulatory filings, clinical trial registries, and published peer-reviewed literature to establish contextual validity and ensure that device performance claims are grounded in clinical practice.

Secondary analysis draws on device specifications, patent literature, and public policy documentation to map technology trajectories and supply-chain dependencies. Where appropriate, device feature comparisons and technology maturity assessments are applied to identify generational shifts and likely user experience differentials. Data synthesis leverages cross-validation techniques to reconcile divergent source signals and highlight areas of consensus and uncertainty. The methodology deliberately emphasizes transparency in source attribution and recognizes limitations related to rapidly evolving regulatory decisions and emerging clinical data, recommending periodic updates to maintain relevance.

Ethical considerations, including patient privacy and informed consent during interviews, guided the primary research process, and analytic assumptions are documented to facilitate reproducibility. This structured approach ensures that findings reflect both lived experience and technical realities, providing decision-makers with actionable intelligence that balances innovation potential with practical deployment considerations.

Concluding synthesis of clinical, commercial, and operational imperatives that must be aligned to realize the full promise of tubeless insulin pump technologies

In conclusion, tubeless insulin pumps are reshaping the therapeutic landscape by offering a more discreet, user-friendly alternative to traditional pump systems while converging with continuous monitoring and connected-care platforms. The interplay between product design, clinical evidence, and commercial execution determines how quickly and broadly these devices will be incorporated into routine diabetes management. Stakeholders must therefore balance innovation with pragmatic evidence generation, regulatory strategy, and channel-specific enablement to ensure that device advances translate into sustained improvements in patient outcomes and health system efficiencies.

Strategic resilience will also be critical as external factors such as trade policy and supply-chain dynamics introduce cost and availability considerations. Firms that invest in diversified sourcing, near-term clinical validation, and adaptable pricing will better protect access and preserve competitive position. Ultimately, the greatest opportunities lie with organizations that couple technical excellence with a deep commitment to patient-centered service models, interoperable data strategies, and collaborative engagement with clinical and payer communities. By doing so, they can move beyond product differentiation to create durable solutions that meaningfully improve the lived experience of people with diabetes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tubeless Insulin Pumps Market, by Type Of Diabetes

  • 8.1. Type 1 Diabetes
  • 8.2. Type 2 Diabetes

9. Tubeless Insulin Pumps Market, by Connectivity

  • 9.1. Bluetooth
  • 9.2. Cellular

10. Tubeless Insulin Pumps Market, by Sensor Wear Duration

  • 10.1. Fourteen Day
  • 10.2. Seven Day

11. Tubeless Insulin Pumps Market, by Price Range

  • 11.1. Economy
  • 11.2. Mid Range
  • 11.3. Premium

12. Tubeless Insulin Pumps Market, by Technology Generation

  • 12.1. First Generation
  • 12.2. Second Generation

13. Tubeless Insulin Pumps Market, by End User

  • 13.1. Adults
  • 13.2. Pediatrics

14. Tubeless Insulin Pumps Market, by Distribution Channel

  • 14.1. Online
  • 14.2. Offline

15. Tubeless Insulin Pumps Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Tubeless Insulin Pumps Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Tubeless Insulin Pumps Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Tubeless Insulin Pumps Market

19. China Tubeless Insulin Pumps Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Abbott Laboratories
  • 20.6. Advanced Microfluidics SA
  • 20.7. APEX Medical Devices
  • 20.8. Ascensia Diabetes Care
  • 20.9. Beta Bionics, Inc.
  • 20.10. Bigfoot Biomedical, Inc.
  • 20.11. Cam Med LLC
  • 20.12. CareMedi Co., Ltd.
  • 20.13. Cellnovo Group plc
  • 20.14. CeQur Corporation
  • 20.15. Debiotech S.A.
  • 20.16. Diabeloop SAS
  • 20.17. EOFlow Co., Ltd.
  • 20.18. F. Hoffmann-La Roche Ltd.
  • 20.19. Insulet Corporation
  • 20.20. Johnson & Johnson
  • 20.21. Luna Health Inc.
  • 20.22. Medipacs Inc.
  • 20.23. Medtrum Technologies Inc.
  • 20.24. MicroPort Scientific Corporation
  • 20.25. Modular Medical, Inc.
  • 20.26. PharmaSens AG
  • 20.27. Tandem Diabetes Care, Inc.
  • 20.28. Terumo Corporation
  • 20.29. Valeritas Holdings, Inc.
  • 20.30. ViCentra B.V.
  • 20.31. Ypsomed AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TUBELESS INSULIN PUMPS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TUBELESS INSULIN PUMPS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES TUBELESS INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA TUBELESS INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY BLUETOOTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY BLUETOOTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY BLUETOOTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY CELLULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY CELLULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY CELLULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY FOURTEEN DAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY FOURTEEN DAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY FOURTEEN DAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY SEVEN DAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY SEVEN DAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY SEVEN DAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY ECONOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY ECONOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY ECONOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY MID RANGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY MID RANGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY MID RANGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY PREMIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY PREMIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY PREMIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS TUBELESS INSULIN PUMPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE TUBELESS INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST TUBELESS INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC TUBELESS INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN TUBELESS INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GCC TUBELESS INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GCC TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 130. GCC TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 132. GCC TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 134. GCC TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GCC TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION TUBELESS INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS TUBELESS INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. G7 TUBELESS INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. G7 TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 154. G7 TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 155. G7 TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 156. G7 TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 157. G7 TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 158. G7 TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. G7 TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. NATO TUBELESS INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. NATO TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 162. NATO TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 163. NATO TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 164. NATO TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 165. NATO TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 166. NATO TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. NATO TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL TUBELESS INSULIN PUMPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES TUBELESS INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA TUBELESS INSULIN PUMPS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA TUBELESS INSULIN PUMPS MARKET SIZE, BY TYPE OF DIABETES, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA TUBELESS INSULIN PUMPS MARKET SIZE, BY CONNECTIVITY, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA TUBELESS INSULIN PUMPS MARKET SIZE, BY SENSOR WEAR DURATION, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA TUBELESS INSULIN PUMPS MARKET SIZE, BY PRICE RANGE, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA TUBELESS INSULIN PUMPS MARKET SIZE, BY TECHNOLOGY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA TUBELESS INSULIN PUMPS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA TUBELESS INSULIN PUMPS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)